Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives.
about
The therapeutic potential of genome editing for β-thalassemiaInfiltrative CardiomyopathiesThe Diagnostic Value of Pulsed Wave Tissue Doppler Imaging in Asymptomatic Beta- Thalassemia Major Children and Young Adults; Relation to Chemical Biomarkers of Left Ventricular Function and Iron Overload.Comparison of Doppler echocardiographic and tissue Doppler velocity data in beta-thalassaemia major with high and normal NT-proBNP levels of children in the south-east region of Turkey.Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram AnalysisCardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.Optimal method for early detection of cardiac disorders in thalassemia major patients: magnetic resonance imaging or echocardiography?Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration.Heart Rate Variability as an Alternative Indicator for Identifying Cardiac Iron Status in Non-Transfusion Dependent Thalassemia PatientsAssessment of Myocardial Performance Index and Aortic Elasticity in Patients With Beta-Thalassemia Major.Association between vitamin D levels and left ventricular function and NT-proBNP levels among thalassemia major children with iron overloadCombined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded RatsIncreased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury.Investigation of molecular heterogeneity of β-thalassemia disorder in District Charsadda of PakistanCorrelation of N-terminal pro-B-type natriuretic peptide levels and cardiac magnetic resonance imaging T2* in patients with β-thalassaemia major.Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.Iron chelation therapy in the management of transfusion-related cardiac iron overload.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy?Cardiac complications in beta-thalassemia: From mice to men.Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injuryMitochondrial Therapies in Heart Failure.Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of EchocPulmonary hypertension associated with thalassemia syndromes.Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management.Mortality and cancer incidence among patients treated with recombinant growth hormone during childhood in Israel.The effect of metoprolol succinate on the cardiac function of patients with thalassaemia cardiomyopathy: a double-blind randomised study.Comparison of right and left side heart functions in patients with thalassemia major, patients with thalassemia intermedia, and control groupEffects of digoxin on cardiac iron content in rat model of iron overload.Cardiac and pulmonary dysfunction in asymptomatic beta-thalassanemia major.Treatment and complications of thalassemia major in Guangxi, Southern China.Asymmetric dimethylarginine levels in children with β-thalassemia and their correlations to tricuspid regurgitant jet velocity.Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment-A Systematic Review.A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice.The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients.Increased sympathovagal imbalance evaluated by heart rate variability is associated with decreased T2* MRI and left ventricular function in transfusion-dependent thalassemia patients.Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population.Value of speckle tracking echocardiography for detection of clinically silent left ventricular dysfunction in patients with β-thalassemia.Assessment of left ventricular and atrial diastolic function using two-dimensional (2D) strain imaging in patients with β-thalassemia major.
P2860
Q26766232-2E0A85BD-FEE5-480F-AE07-AEBD1CC47005Q26798533-3C852738-69DA-4845-933D-04AF7CF6E523Q30402562-24C76175-B46A-4CEF-8F2E-4E23C9389DA7Q31042151-4F6E2E26-9261-40F6-8623-D38F8CCCE79CQ33657240-975113B9-5668-4024-884C-6C6A96E2DCB8Q33812953-F1EE63D6-7E93-42A7-84ED-7EB56FC04971Q34302477-FFE4654D-CDD8-4F5E-93D6-804358C674FEQ34761250-4A49B4BE-749F-4B38-A875-B22841037D97Q35288031-42F8980A-85F7-4D66-A891-0BD7604ABECFQ35665822-A71406C9-58E7-4DC4-8F06-946F3FCF9601Q36009718-86214FEF-6C76-4114-B62D-F33857DC7E3AQ36026047-9EF5E615-D727-40A9-94CD-CF9AE5E61392Q36080315-F24455DE-4710-4EA9-912F-311B6B378687Q36141698-9AC7430A-76F1-495E-BC05-5DCC6F272AD4Q36876520-45A1F1E9-0CD4-42E5-8036-D49A396B3712Q37417308-4AF3441C-5B6E-498C-9438-0E2508EE730EQ37695691-B8705662-C8DA-4195-8406-7FB1CA938079Q37992181-FBE18894-A8F0-4C6C-9D1A-259D5B0C390DQ38166071-79110CE0-A617-4287-831F-A8DEBB95CBF7Q38311768-651E7952-BE15-4201-9E38-9824126D2B57Q38686059-0E93D73D-C16C-44E4-AEEB-E69D548290B8Q38741123-3750F4D6-6EFA-4E0A-A9E2-B059FCCC1C03Q38759545-C613387C-469C-429C-B2B9-779ADDABEB7AQ38782767-19B89802-0DF3-48AF-BF62-00BECCA9F8C7Q38786355-C2441B15-B9F8-4C2D-9C4E-091033BFDD69Q39045339-00858900-9A2F-42B6-8DDB-8B1D07405B4AQ39689713-D374DD53-2425-4B77-94D8-DB6AEBC99EB7Q40209714-6D8A9464-67B2-4BA8-A820-4743FBFA182DQ41632886-5F92CB5A-6CFA-473A-9B2C-D019AB20B029Q41856386-E4A98EA6-D36C-4CAE-8867-C82266051138Q43598479-863A1B01-15F4-4CB9-9276-11E092A1FAECQ44639942-DD7D560F-B368-47C2-9ACB-9E29E2A52C6FQ46789974-74D38BDC-2F2D-40DD-89B5-70A8624C8293Q47162150-9C55F144-D68A-45C3-BF5F-C9541EFE1639Q47931907-2B17601A-1975-4D4B-B17C-222835E51CE8Q48204122-BE381193-07AE-463D-A1E7-45A42043956BQ48539558-C0B52752-173B-4750-AD9E-83CEC48D5A37Q48557800-DB9E87CB-8FC6-4739-A6B4-6B7265EACCFCQ48561018-0E8DA4FE-01C7-41AD-BAF7-626BC68A2DBFQ48707893-C900D096-26D1-4F73-B594-1494A524ED31
P2860
Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@en
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@nl
type
label
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@en
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@nl
prefLabel
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@en
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@nl
P2093
P1476
Beta-thalassemia cardiomyopath ...... ions, and future perspectives.
@en
P2093
Andre Keren
Athanasios Aessopos
Dimitrios Farmakis
Dimitrios T Kremastinos
Dimitrios Tsiapras
Eftychia Hamodraka
George Hahalis
P304
P356
10.1161/CIRCHEARTFAILURE.109.913863
P577
2010-05-01T00:00:00Z